Who are MenACYW135 polysaccharide vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MCV4, MenACWY, Meningococcal ACWY Conjugate Vaccine, MenACWY, MenitorixTM, MPSV4.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/menacyw135-polysaccharide-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

MenACYW135 polysaccharide vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MenACYW135 polysaccharide vaccine (MenACYW135 polysaccharide vaccine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate polysaccharide vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate polysaccharide vaccine Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MenACYW135 polysaccharide vaccine (MenACYW135 polysaccharide vaccine) — Sanofi. MenACYW135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y polysaccharide antigens.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MenACYW135 polysaccharide vaccine TARGET	MenACYW135 polysaccharide vaccine	Sanofi	phase 3	Conjugate polysaccharide vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MCV4	MCV4	CanSino Biologics Inc.	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MenACWY	MenACWY	LimmaTech Biologics AG	marketed	Conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
Meningococcal ACWY Conjugate Vaccine, MenACWY	Meningococcal ACWY Conjugate Vaccine, MenACWY	GlaxoSmithKline	phase 3	Conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MenitorixTM	MenitorixTM	GlaxoSmithKline	phase 3	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MPSV4	MPSV4	CanSino Biologics Inc.	phase 3	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Conjugate polysaccharide vaccine class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MenACYW135 polysaccharide vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/menacyw135-polysaccharide-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab